Related Experiment Video
Updated: Jun 14, 2025

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Resistance of estrogen receptor function to BET bromodomain inhibition is mediated by transcriptional coactivator
Abstract:
The Bromodomain and Extra-Terminal Domain (BET) family of proteins are critical chromatin readers that bind to acetylated histones through their bromodomains to activate transcription. Here, we reveal that bromodomain inhibition fails to repress oncogenic targets of estrogen receptor due to an intrinsic transcriptional mechanism. While bromodomains are necessary for the transcription of many genes, BRD4 binds to estrogen receptor binding sites and activates transcription of critical oncogenes independently of its bromodomains. BRD4 associates with the Mediator complex and disruption of Mediator complex reduces BRD4's enhancer occupancy. Profiling changes in the post-initiation RNA polymerase II (Pol II)-associated factors revealed that BET proteins regulate interactions between Pol II and elongation factors SPT5, SPT6, and PAF1 complex, which associate with BET proteins independently of their bromodomains and mediate their transcription elongation effect. Our findings highlight the importance of bromodomain-independent functions and interactions of BET proteins in the development of future therapeutic strategies.
Insights
Bromodomain inhibition fails to repress estrogen receptor targets because BRD4 activates oncogenes independently of its bromodomains. BET proteins also regulate transcription elongation through bromodomain-independent interactions.
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Biology
Background:
- Bromodomain and Extra-Terminal Domain (BET) proteins are key epigenetic readers that regulate gene transcription.
- BET proteins bind to acetylated histones via their bromodomains, typically activating gene expression.
Purpose of the Study:
- To investigate the mechanism by which BET proteins regulate oncogenic gene transcription, particularly in the context of estrogen receptor signaling.
- To determine if BET protein function is solely dependent on its bromodomains or if other mechanisms are involved.
Main Methods:
- Analysis of gene expression in response to bromodomain inhibition.
- Investigating the interaction of BRD4 with estrogen receptor binding sites and the Mediator complex.
- Profiling of RNA polymerase II (Pol II)-associated factors and elongation factors.
Main Results:
- Bromodomain inhibition did not repress key oncogenic targets of the estrogen receptor.
- BRD4 activates transcription of critical oncogenes independently of its bromodomains by binding to estrogen receptor sites.
- BRD4 interacts with the Mediator complex, and its disruption reduces BRD4 occupancy at enhancers.
- BET proteins regulate Pol II interactions with elongation factors (SPT5, SPT6, PAF1 complex) independently of bromodomains, impacting transcription elongation.
Conclusions:
- BET proteins possess critical bromodomain-independent functions in regulating oncogenic transcription.
- BRD4's interaction with the Mediator complex and elongation factors is crucial for its transcriptional activity.
- These findings suggest novel therapeutic strategies targeting bromodomain-independent BET protein functions.
Related Concept Videos
Cooperative Binding of Transcription Regulators
Co-activators and Co-repressors
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
RNA Polymerase II Accessory Proteins
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....

